122 Grants (Page 1 of 5)
2008
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7671), $456USD, 12/01/2007 -- 05/31/2008
 
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7593), $67,013USD, 12/01/2007 -- 05/31/2008
 
ADULT AIDS CLINICAL TRIALS UNIT
Goldman, Mitchell
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 3U01AI025859-18S4), $452,645USD, 01/01/2000 -- 12/31/2008
 
A MULTICENTER, OPEN-LABEL, CONTROLLED PHASE II STUDY TO EVALUATE SAFETY AND I
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7693), $11,812USD, 12/01/2007 -- 05/31/2008
 
A MULTICENTER, OPEN-LABEL PHASE I/II STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7672), $21,581USD, 12/01/2007 -- 05/31/2008
 
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7616), $455USD, 12/01/2007 -- 05/31/2008
 
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7638), $6,815USD, 12/01/2007 -- 05/31/2008
 
A PHASE III B, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITO
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7670), $47,250USD, 12/01/2007 -- 05/31/2008
 
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7611), $7,723USD, 12/01/2007 -- 05/31/2008
 
PHASE I B/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070 (AN ORALLY
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7643), $10,904USD, 12/01/2007 -- 05/31/2008
 
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-36-7659), $455USD, 12/01/2007 -- 05/31/2008
2007
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8364), $1,900USD, 12/01/2006 -- 11/30/2007
 
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8286), $281,088USD, 12/01/2006 -- 11/30/2007
 
ADULT AIDS CLINICAL TRIALS UNIT
Goldman, Mitchell
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 3U01AI025859-18S3), $1,030,283USD, 01/01/2000 -- 12/31/2008
 
A MULTICENTER, OPEN-LABEL, CONTROLLED PHASE II STUDY TO EVALUATE SAFETY AND I
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8386), $49,547USD, 12/01/2006 -- 11/30/2007
 
A MULTICENTER, OPEN-LABEL PHASE I/II STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8365), $90,521USD, 12/01/2006 -- 11/30/2007
 
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8309), $1,906USD, 12/01/2006 -- 11/30/2007
 
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8331), $28,585USD, 12/01/2006 -- 11/30/2007
 
A PHASE III B, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITO
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8363), $198,190USD, 12/01/2006 -- 11/30/2007
 
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8304), $32,395USD, 12/01/2006 -- 11/30/2007
 
PHASE I B/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070 (AN ORALLY
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8336), $45,736USD, 12/01/2006 -- 11/30/2007
 
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-35-8352), $1,907USD, 12/01/2006 -- 11/30/2007
2006
ADULT AIDS CLINICAL TRIALS UNIT
Goldman, Mitchell
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 3U01AI025859-18S2), $1,386,661USD, 01/01/2000 -- 12/31/2008
 
ADULT AIDS CLIN TRIAL GRP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) - A5001
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5162), $190,784USD, 12/01/2005 -- 11/30/2006
 
A MULTICENTER, OPEN-LABEL PHASE I/II STUDY TO EVALUATE SAFETY AND IMMUNOGENIC
Goldman, Mitchell J
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-34-5273), $5,116USD, 12/01/2005 -- 11/30/2006